Apellis Stock Story

APLS

- USA Stock

USD 44.81 0.33 0.74%

Macroaxis Story

Today we may see the proof that Brickell Biotech would recover slower from the current drop as its shares fell 2.44% to Apellis Pharmaceuticals's 0.7%. As many investors are getting excited about healthcare space, Apellis Pharmaceuticals and Brickell Biotech may be going in opposite directions. We are going to discuss some of the competitive aspects of both Apellis and Brickell.

Published over six months ago

View all stories for Apellis Pharmaceuticals | View All Stories

Will Brickell Biotech (NASDAQ:BBI) and Apellis Pharmaceuticals (NASDAQ:APLS) deliver in December?

By analyzing existing essential indicators between Apellis Pharmaceuticals and Brickell, you can compare the effects of market volatilities on both companies' prices and check if they can diversify away market risk if combined in one of your portfolios. You can also utilize pair trading strategies for matching a long position in Brickell with a short position in Apellis Pharmaceuticals. Check out our pair correlation module for more information.

Let's begin by analyzing the assets.

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Apellis Pharmaceuticals has an asset utilization ratio of 216.7 percent. This connotes that the company is making $2.17 for each dollar of assets. An increasing asset utilization means that Apellis Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.

Will Brickell Biotech (NASDAQ:BBI) and Apellis Pharmaceuticals (NASDAQ:APLS) deliver in December?

How important is Apellis Pharmaceuticals's Liquidity

Apellis Pharmaceuticals financial leverage refers to using borrowed capital as a funding source to finance Apellis Pharmaceuticals ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Apellis Pharmaceuticals financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Apellis Pharmaceuticals's total debt and its cash.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions.

It is good to see analyst projects for Apellis Pharmaceuticals, but it might be worth checking our own buy vs. sell analysis

An Additional Perspective On Apellis Pharmaceuticals

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.

Revenue Breakdown

Let me now analyze Apellis Pharmaceuticals revenue. Based on the latest financial disclosure, Apellis Pharmaceuticals reported 251.27 M of revenue. This is 96.71% lower than that of the Healthcare sector and 66.18% lower than that of the Biotechnology industry. The revenue for all United States stocks is 97.34% higher than that of Apellis Pharmaceuticals. As for Brickell Biotech we see revenue of 337 K, which is 99.95% lower than that of the Biotechnology

	Apellis	251.27 Million
	Sector	742.91 Million
	Brickell	337,000

251.3 M

Apellis

742.9 M

Sector

Brickell

Apellis Pharmaceuticals has a good chance to finish above $35 in 2 months

Latest kurtosis is at 27.19. Apellis Pharmaceuticals exhibits very low volatility with skewness of -4.25 and kurtosis of 27.19. However, we advise investors to further study Apellis Pharmaceuticals technical indicators to make sure all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Apellis Pharmaceuticals' stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Apellis Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Apellis Pharmaceuticals Implied Volatility

Apellis Pharmaceuticals' implied volatility exposes the market's sentiment of Apellis Pharmaceuticals stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Apellis Pharmaceuticals' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Apellis Pharmaceuticals stock will not fluctuate a lot when Apellis Pharmaceuticals' options are near their expiration.

While some companies in the biotechnology industry are either recovering or due for a correction, Apellis Pharmaceuticals may not be performing as strong as the other in terms of long-term growth potentials. With a relatively neutral outlook on the latest economy, it is better to hold off any trading of Apellis as the current risk-reward utility is not appealing enough. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Apellis Pharmaceuticals.

Editorial Staff

Raphi Shpitalnik is a Junior Member of Macroaxis Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time base at the beginning of the pandemic and eventually acquired a real test for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI. View Profile

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Apellis Pharmaceuticals. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2022 Macroaxis LLC